Year of publication:
This product can be paid via invoice with a valid PO number.
Find out more
Organisations that manufacture or import biocidal products must have a valid biocidal product authorisation before placing the product on the market. This needs to be done through the European Chemicals Agency (ECHA) for products placed on the EU market and the Health and Safety Executive (HSE) for products being placed on the GB market.
To help businesses navigate the requirements for biocidal products authorisation in the EU and GB, NCEC has created a comprehensive Biocidal Product Regulation Compliance Report.
Our biocidal product regulation compliance report is driven by our experts’ regulatory knowledge and close links with regulatory bodies such as ECHA, the HSE and EU Member State competent authorities. The report includes thousands of hours of review, extensive discussions with each regulatory body and the compilation of comprehensive processes for biocide approval in both regions.
The report has been authored by NCEC’s regulatory experts and explains the practical steps that companies need to take to meet the requirements for biocidal product authorisation, and active substance approval. Our experts have carried out extensive review of the applicable regulations and guidance documents, seeking clarification from the HSE and ECHA as required. The report outlines the key requirements of both biocidal product regimes and what this practically means for businesses.
NCEC’s report includes:
- Overview of EU and GB BPR.
- Active substance approval process, including scope, exclusions and renewal requirements.
- Biocidal product approval process, including information requirements and different approval pathways.
- Analysis of the key differences between GB BPR and EU BPR and the approval pathways.
- Details on product labelling.
- Consolidation of each EU Member State BPR provision and competent authorities.
- General report (£2,495+VAT) – A comprehensive summary of the current BPR requirements and explanations of the different authorisation pathways.